Precision BioSciences, Inc., a clinical-stage biotechnology company, has appointed Alex Kelly chief corporate affairs officer.
Kelly comes to the company from Allergan, where he was executive vice president, corporate affairs and chief communications officer, as well as president of The Allergan Foundation. In those roles, he developed internal and external messaging and supported Allergan’s recent merger with AbbVie.
Kelly has also served as senior VP, chief integration officer at Actavis and senior VP, chief communications officer, public affairs and investor relations at Forest Labs.
In his new role, he will join the senior leadership team and oversee all investor relations and corporate communications. "Alex brings valuable and meaningful experience leading corporate affairs for some of the most successful healthcare companies in the industry,” said Precision CEO Matt Kane.